No Data
No Data
Express News | Brainstorm Cell Therapeutics Inc Files for Mixed Shelf Offering of up to $172.6 Mln - SEC Filing
Maxim Group Maintains Brainstorm Cell Therapeutics(BCLI.US) With Buy Rating, Maintains Target Price $2
Maxim Group analyst Jason McCarthy maintains $Brainstorm Cell Therapeutics(BCLI.US)$ with a buy rating, and maintains the target price at $2.According to TipRanks data, the analyst has a success
Buy Rating Affirmed for Brainstorm Cell Therapeutics Amid Strategic Advances and Robust Financials
Brainstorm Cell Therapeutics Inc. (BCLI) Q2 2024 Earnings Call Transcript Summary
Brainstorm Cell Therapeutics | 10-Q: Q2 2024 Earnings Report
Earnings Flash (BCLI) BRAINSTORM CELL THERAPEUTICS Reports Q2 Loss $-0.04 Per Share